Company Description
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Puerto Rico, Costa Rica, and internationally.
The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies.
In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines.
Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets.
Integer Holdings Corporation was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016.
The company was founded in 1970 and is headquartered in Plano, Texas.
| Country | United States |
| Founded | 1970 |
| IPO Date | Sep 29, 2000 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 11,000 |
| CEO | Joseph Dziedzic |
Contact Details
Address: 5830 Granite Parkway, Suite 1150 Plano, Texas 75024 United States | |
| Phone | 214 618 5243 |
| Website | integer.net |
Stock Details
| Ticker Symbol | ITGR |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001114483 |
| CUSIP Number | 45826H109 |
| ISIN Number | US45826H1095 |
| Employer ID | 16-1531026 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Joseph W. Dziedzic | President, Chief Executive Officer and Director |
| Diron Smith | Executive Vice President and Chief Financial Officer |
| Payman Khales | Chief Operating Officer |
| John Harris | Executive Vice President of Global Operations and Manufacturing Strategy |
| Jim Stephens | President of Cardiac Rhythm Management and Neuromodulation |
| Tom P. Thomas | Vice President, Corporate Controller and Principal Accounting Officer |
| Kristen Marie Stewart C.F.A. | Director of Investor Relations |
| Lindsay Krause Blackwood J.D. | Senior Vice President, General Counsel, Chief Ethics and Compliance Officer and Corporate Secretary |
| Kirk K. Thor Ph.D. | Executive Vice President and Chief Human Resources Officer |
| Margaret Carthy | Executive Vice President of Global Quality and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | 10-Q | Quarterly Report |
| Apr 24, 2025 | 8-K | Current Report |
| Apr 24, 2025 | 8-K | Current Report |
| Apr 15, 2025 | SCHEDULE 13G/A | Filing |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 7, 2025 | ARS | Filing |
| Apr 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 7, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |